Cyclin-dependent kinase (CDK) 4/6 inhibitors have become a cornerstone in the treatment of hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, demonstrating significant efficacy in both early and metastatic stages. However, despite their clinical benefits, emerging evidence from health databases, real-world studies, and case reports highlight potential cardiovascular risks, including QTc prolongation and thrombosis. This review aims to comprehensively evaluate the cardiovascular safety profiles of the three FDA-approved CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—in patients with HR+/HER2- advanced breast cancer. Specifically, it compares the risks of QTc prolongation and thrombosis associated with these agents.
Data source
A literature search was conducted using PubMed, ClinicalTrials.gov, and manual searches of relevant articles.
Study selection
Studies included in this review were those that reported CDK4/6 inhibitor cardiovascular outcomes, specifically QTc prolongation and thrombosis, in patients with advanced breast cancer.
Conclusion
The review highlights significant differences in the cardiovascular safety profiles of CDK4/6 inhibitors. Ribociclib is associated with the highest risk of QTc prolongation, with incidence rates ranging from 4.5% to 13.3% in RCTs, while palbociclib demonstrates a more favorable profile, with QTc prolongation reported in less than 1% of cases. Abemaciclib, although not linked to QTc prolongation, has the highest reported incidence of thrombosis, ranging from 2.0% to 4.9% in RCTs. Real-world data revealed thrombosis incidence rates as high as 17% among patients treated with CDK4/6 inhibitors. Thus, future research must ascertain the cardiovascular safety profiles of different CDK4/6 inhibitors and develop effective cardiovascular toxicity prevention strategies.
MuradBReisPCADeberaldini MarinhoA, et al.QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. JNCI Cancer Spectr2024; 8: pkae078.
2.
GaoSLiYHeZ, et al.Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review. Expert Opin Drug Saf2023; 22: 599–609.
3.
GeorgeMAQureshiSOmeneC, et al.Clinical and pharmacologic differences of CDK4/6 inhibitors in breast cancer. Front Oncol2021; 11: 693104. https://doi.org/10.3389/fonc.2021.693104
4.
GervasoLMonteroAJJiaX,et al.Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. J Thromb Haemostasis2020; 18: 162–168.
5.
RoyceMOsgoodCMulkeyF, et al.FDA Approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer. J Clin Oncol2022; 40: 1155–1162.
6.
JohnstonSRDHarbeckNHeggR, et al.Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol2020; 38: 3987–3998.
7.
BertucciFFinettiPMamessierE,et al.The MonarchE trial: improving the clinical outcome in HR+/HER2− early breast cancer: recent results and next steps. Cancer Commun2023; 43: 938–942.
8.
SantoniMOcchipintiGRomagnoliE, et al.Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications. BioDrugs2019; 33: 613–620.
9.
WangZLiJWangY,et al.Palbociclib improves cardiac dysfunction in diabetic cardiomyopathy by regulating Rb phosphorylation. Am J Transl Res2019; 11: 3481–3489.
10.
PapageorgiouCZagouriFTampakisK, et al.Vascular inflammation and cardiovascular burden in metastatic breast cancer female patients receiving hormonal treatment and CDK 4/6 inhibitors or everolimus. Front Cardiovasc Med2021; 8: 638895.
11.
HortobagyiGNStemmerSMBurrisHA, et al.Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med2022; 386: 942–950.
12.
HortobagyiGNStemmerSMBurrisHA, et al.Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med2016; 375: 1738–1748.
13.
SlamonDJNevenPChiaS, et al.Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol2021; 32: 1015–1024.
14.
SlamonDJNevenPChiaS, et al.Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med2020; 382: 514–524.
15.
LuYSImSAColleoniM, et al.Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in Pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res2022; 28: 851–859.
16.
TripathyDImSAColleoniM, et al.Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol2018; 19: 904–915.
17.
ImS-ALuY-SBardiaA, et al.Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med2019; 381: 307–316.
18.
KalinskyKO'DeaACiglerT, et al.Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol2023; 41: 4004–4013.
19.
FinnRSMartinMRugoHS, et al.Palbociclib and letrozole in advanced breast cancer. N Engl J Med2016; 375: 1925–1936.
20.
CristofanilliMRugoHSImSA, et al.Overall survival with palbociclib and fulvestrant in women with HRþ/HER2̄ ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clin Cancer Res2022; 28: 3433–3442.
21.
CristofanilliMTurnerNCBondarenkoI, et al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol2016; 17: 425–439.
22.
TurnerNCRoJAndréF, et al.Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med2015; 373: 209–219.
23.
GnantMDueckACFrantalS, et al.Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/ AFT-05/BIG-14-03). J Clin Oncol2021; 40: 282–293.
24.
MayerELDueckACMartinM, et al.Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2021; 22: 212–222.
25.
SledgeGWToiMNevenP, et al.Journal of Clinical Oncology Monarch 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol2017; 35: 2875–2884.
26.
SledgeGWToiMNevenP, et al.The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy - MONARCH 2: a randomized clinical trial. JAMA Oncol2020; 6: 116–124.
27.
GoetzMPToiMCamponeM, et al.MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol2017; 35: 3638–3646.
28.
ZhangQYSunTYinYM, et al.MONARCH Plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol2020; 12: 1758835920963925.
29.
DurairajCRuiz-GarciaAGauthierER, et al.Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs2018; 29: 271–280.
30.
FinnRSRugoHSGelmonKA, et al. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor‒positive_human epidermal growth factor receptor 2‒negative advanced breast cancer updated analysis with up to 5 years of follow-up. Oncologist2021; 26: 749–755.
31.
TheinKZBallSZawMH, et al.Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients. Ann Oncol2018; 29: viii606.
32.
LiuYSDongKParkC. Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with advanced breast cancer: a systematic review and network meta-analysis. Rev Cardiovasc Med2023; 24: 309.
33.
FradleyMGNguyenNHKMadnickD, et al.Adverse cardiovascular events associated with cyclin-dependent kinase 4/6 inhibitors in patients with metastatic breast cancer. J Am Heart Assoc2023; 12: e029361.
34.
WestMTSmithCEKaempfA, et al.CDK 4/6 Inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol2021; 106: 634–642.
35.
WatsonNWWanderSAShatzelJJ,et al.Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer. Cancer2022; 128: 3224–3232.
36.
GervasoLMonteroAJJiaX,et al.Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. J Thromb Haemostasis2020; 18: 162–168.
37.
Abdel-RazeqHSharafBAlmasriR, et al.Thromboembolic events in patients with HER2-negative, hormone receptor-positive, metastatic breast cancer treated with ribociclib combined with letrozole or fulvestrant: a real-world data. Cancer Manag Res2022; 14: 1033–1041.
38.
LyonARLópez-FernándezTCouchLS, et al.2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J2022; 43: 4229–4261.
39.
Bergler-KleinJRainerPPWallnerM, et al.Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies: position paper of the Heart Failure Working Group of the Austrian Society of Cardiology. Wien Klin Wochenschr2022; 134: 654–674.
